



What is claimed is:

1. The compound AA-896-B1 which has the structure:




5



or pharmaceutically acceptable salts thereof.




- 10 2. The compound AA-896-B5 which has the structure:



or pharmaceutically acceptable salts thereof.



15

3. The compound AA-896-B2 which has the structure:



5 or pharmaceutically acceptable salts thereof.



4. The compound AA-896-A2 which has the structure:



10

or pharmaceutically acceptable salts thereof.


5. The compound AA-896-A1 which has the structure:



or pharmaceutically acceptable salts thereof.

5




6. The compound AA-896-B3 which has the structure:



or pharmaceutically acceptable salts thereof.




10

7. The compound AA-896-B4 which has the structure:




5 or pharmaceutically acceptable salts thereof.

8. The compound AA-896-A4 which has the structure:




10 or pharmaceutically acceptable salts thereof.

9. The compound AA-896-C2 which has the structure:




or pharmaceutically acceptable salts thereof.

5 10. The compound AA-896-C1 which has the structure:






or pharmaceutically acceptable salts thereof.

11. The compound AA-896-D2 which has the structure:



or pharmaceutically acceptable salts thereof.




12. The compound AA-896-D3 which has the structure:



or pharmaceutically acceptable salts thereof.

5



13. The compound AA-896-D1 which has the structure:



or pharmaceutically acceptable salts thereof.


10

14. The compound AA-896-A3 which has the structure:



5 or pharmaceutically acceptable salts thereof.

15. The compound AA-896-C3 which has the structure:




10 or pharmaceutically acceptable salts thereof.






18. The compound AA-896-C4 which has the structure:



or pharmaceutically acceptable salts thereof.


19. The compound AA-896-A5 which has the structure:



5

or pharmaceutically acceptable salts thereof.

20. The compound AA-896-C5 which has the structure:




10

or pharmaceutically acceptable salts thereof.

15



21. The compound AA-896-D4 which has the structure:



or pharmaceutically acceptable salts thereof.

5

22. The compound AA-896-A6 which has the structure:



10 or pharmaceutically acceptable salts thereof.

23. A process for producing the compound of claim 1,

said process comprising:

15

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

24. A process for producing the compound of claim 2,

said process comprising:

5

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

10

25. A process for producing the compound of claim 3,

said process comprising:

15

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

20

26. A process for producing the compound of claim 4,

said process comprising:

25

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

30

27. A process for producing the compound of claim 5,

said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

5

28. A process for producing the compound of claim 6,

said process comprising:

10 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

15 29. A process for producing the compound of claim 7,

said process comprising:

20 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

30. A process for producing the compound of claim 8,

25

said process comprising:

30 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

31. A process for producing the compound of claim 9,

said process comprising:

- 5     cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

10    32. A process for producing the compound of claim 10,

said process comprising:

- 15    cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

20    33. A process for producing the compound of claim 11,

said process comprising:

- 25    cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

34. A process for producing the compound of claim 12,

30    said process comprising:

- cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889, and LL4892 or a mutant thereof under

aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

35. A process for producing the compound of claim 13,

5

said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

10

36. A process for producing antibiotic the compound of claim 14,

15

said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

20

37. A process for producing the compound of claim 15,

said process comprising:

25

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

30

38. A process for producing the compound of claim 16,

said process comprising:

5 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

39. A process for producing the compound of claim 17,  
said process comprising:  
10 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

15 40. A process for producing the compound of claim 20,  
said process comprising:  
20 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

25 41. A process for producing the compound of claim 21,  
said process comprising:  
30 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

42. A process for producing the compound of claim 22,  
5  
said process comprising:
- cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774,  
LL4794, LL4802, LL4808 and LL4892 or a mutant thereof under aerobic conditions,  
10 in a suitable culture medium until a recoverable amount of said compound is formed  
in said medium and recovering said compound therefrom.
43. A method for the prevention, treatment or control of bacterial infections in warm-  
blooded animals which comprises providing to said warm-blooded animal a  
15 antibacterially effective amount of the compound according to claim 1 or a  
pharmaceutically acceptable salt thereof.
44. A pharmaceutical composition comprising the compound according to claim 1 in  
association with a pharmaceutically acceptable carrier.  
20
45. A method for the prevention, treatment or control of bacterial infections in warm-  
blooded animals which comprises providing to said warm-blooded animal a  
antibacterially effective amount of the compound according to claim 2 or a  
pharmaceutically acceptable salt thereof.  
25
46. A pharmaceutical composition comprising the compound according to claim 2 in  
association with a pharmaceutically acceptable carrier.
47. A method for the prevention, treatment or control of bacterial infections in warm-  
30 blooded animals which comprises providing to said warm-blooded animal a  
antibacterially effective amount of the compound according to claim 3 or a  
pharmaceutically acceptable salt thereof.



48. A pharmaceutical composition comprising the compound according to claim 3 in association with a pharmaceutically acceptable carrier.
- 5 49. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 4 or a pharmaceutically acceptable salt thereof.
- 10 50. A pharmaceutical composition comprising the compound according to claim 4 in association with a pharmaceutically acceptable carrier.
- 15 51. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 5 or a pharmaceutically acceptable salt thereof.
52. A pharmaceutical composition comprising the compound according to claim 5 in association with a pharmaceutically acceptable carrier.
- 20 53. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 6 or a pharmaceutically acceptable salt thereof.
- 25 54. A pharmaceutical composition comprising the compound according to claim 6 in association with a pharmaceutically acceptable carrier.
- 30 55. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 7 or a pharmaceutically acceptable salt thereof.

56. A pharmaceutical composition comprising the compound according to claim 7 in association with a pharmaceutically acceptable carrier.
57. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a  
5 antibacterially effective amount of the compound according to claim 8 or a pharmaceutically acceptable salt thereof.
58. A pharmaceutical composition comprising the compound according to claim 8 in  
10 association with a pharmaceutically acceptable carrier.
59. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a  
15 antibacterially effective amount of the compound according to claim 9 or a pharmaceutically acceptable salt thereof.
60. A pharmaceutical composition comprising the compound according to claim 9 in association with a pharmaceutically acceptable carrier.
- 20 61. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 10 or a pharmaceutically acceptable salt thereof.
- 25 62. A pharmaceutical composition comprising the compound according to claim 10 in association with a pharmaceutically acceptable carrier.
63. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a  
30 antibacterially effective amount of the compound according to claim 11 or a pharmaceutically acceptable salt thereof.

64. A pharmaceutical composition comprising the compound according to claim 11 in association with a pharmaceutically acceptable carrier.
- 5 65. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 12 or a pharmaceutically acceptable salt thereof.
- 10 66. A pharmaceutical composition comprising the compound according to claim 12 in association with a pharmaceutically acceptable carrier.
- 15 67. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 13 or a pharmaceutically acceptable salt thereof.
- 20 69. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 14 or a pharmaceutically acceptable salt thereof.
- 25 70. A pharmaceutical composition comprising the compound according to claim 14 in association with a pharmaceutically acceptable carrier.
- 30 71. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 15 or a pharmaceutically acceptable salt thereof.

72. A pharmaceutical composition comprising the compound according to claim 15 in association with a pharmaceutically acceptable carrier.
- 5 73. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 16 or a pharmaceutically acceptable salt thereof.
- 10 74. A pharmaceutical composition comprising the compound according to claim 16 in association with a pharmaceutically acceptable carrier.
- 15 75. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 17 or a pharmaceutically acceptable salt thereof.
76. A pharmaceutical composition comprising the compound according to claim 17 in association with a pharmaceutically acceptable carrier.
- 20 77. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 18 or a pharmaceutically acceptable salt thereof.
- 25 78. A pharmaceutical composition comprising the compound according to claim 18 in association with a pharmaceutically acceptable carrier.
- 30 79. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 19 or a pharmaceutically acceptable salt thereof.

80. A pharmaceutical composition comprising the compound according to claim 19 in association with a pharmaceutically acceptable carrier.
- 5 81. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 20 or a pharmaceutically acceptable salt thereof.
- 10 82. A pharmaceutical composition comprising the compound according to claim 20 in association with a pharmaceutically acceptable carrier.
- 15 83. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 21 or a pharmaceutically acceptable salt thereof.
- 20 84. A pharmaceutical composition comprising the compound according to claim 21 in association with a pharmaceutically acceptable carrier.
- 25 85. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of the compound according to claim 22 or a pharmaceutically acceptable salt thereof.
86. A pharmaceutical composition comprising the compound according to claim 22 in association with a pharmaceutically acceptable carrier.
87. A microorganism *Streptomyces spp.* LL-AA896, strain LL4774, or a mutant thereof.
- 30 88. A microorganism *Streptomyces spp.* LL-AA896, strain LL4794, or a mutant thereof.

89. A microorganism *Streptomyces* spp. LL-AA896, strain LL4802, or a mutant thereof.


90. A microorganism *Streptomyces* spp. LL-AA896, strain LL4808, or a mutant thereof.

91. A microorganism *Streptomyces* spp. LL-AA896, strain LL4879, or a mutant thereof.

92. A microorganism *Streptomyces* spp. LL-AA896, strain LL4889, or a mutant thereof.

93. A microorganism *Streptomyces* spp. LL-AA896, strain LL4892, or a mutant thereof.

94. A compound of the formula:




wherein:

R<sup>1</sup> is H or R<sup>4</sup>;

R<sup>2</sup> is H, OH or OCH<sub>3</sub>;

R<sup>3</sup> is H or CH<sub>3</sub>;

R<sup>4</sup> is represented by the formula



n is an integer from 4 to 12;

R<sup>5</sup> is straight and branched alkyl of 1 to 4 carbon atoms, carbamimidoylamino or carbamimidoylhydroxyamino;  
or a pharmaceutically acceptable salt thereof.

5 95. A method for the prevention, treatment or control of bacterial infections in warm-blooded animals which comprises providing to said warm-blooded animal a antibacterially effective amount of a compound according to claim 94 or a pharmaceutically acceptable salt thereof.

10 96. A pharmaceutical composition comprising an effective amount of a compound according to claim 94 in association with a pharmaceutically acceptable carrier.

97. A process for producing the compound of claim 9,

said process comprising:

15

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

20

98. A process for producing the compound of claim 10,

said process comprising:

25

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

30

99. A process for producing the compound of claim 11,

said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

5

100. A process for producing the compound of claim 12,

said process comprising:

10 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889, and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

15 101. A process for producing the compound of claim 13,

said process comprising:

20 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

102. A process for producing the compound of claim 15,

25

said process comprising:

30 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.



103. A process for producing the compound of claim 94,

said process comprising:

- 5 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

10 104. A process for producing the compound of claim 94,

said process comprising:

- 15 cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889, LL4879 and LL4892 or a mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said compound is formed in said medium and recovering said compound therefrom.

20